Oral Answers to Questions

Debate between George Freeman and Rachael Maskell

Tuesday 7th June 2022 Commons Chamber

[Rachael Maskell (York Central) (Lab/Co-op)]

11. What steps he is taking to support business and social business incubator and accelerator hubs.

[The Parliamentary Under-Secretary of State for Business, Energy and Industrial Strategy (George Freeman)]

Incubators and accelerators across the country play a vital role in helping our high-growth start-ups and scale- ups. That is why we continue to fund the strength in places fund, and are investing £100 million to pilot new innovation accelerators. That is also why, on my various tours around clusters, I recently went to the Leicester space and satellite hub, the Leeds digital health and medtech hub in the hon. Lady’s county, the Northumbria University and Ashington further education hub, and the BioYorkshire hub in her area.

[Rachael Maskell]

York’s economic future depends on releasing the talent of our entrepreneurs and social enterprises. To do that, we need to ensure that they have space to innovate and grow. In each of the last four quarters, however, we have seen the loss of 100,000 entrepreneurs, so what investment will be made to ensure that we have the infrastructure in place for the acceleration and incubation of the future business industry?

[George Freeman]

The hon. Lady makes an important point about social enterprises being mainstreamed in the business community. She may have seen the recent report by the all-party parliamentary group for social enterprise, of which I have long been a supporter, that argued that we should mainstream social enterprise in the BEIS policy framework, which is an interesting proposal. We have just announced the biggest increase in research and development and innovation funding—an increase of £25 billion over the next three years. I have asked UK Research and Innovation to focus on that incubation hub infrastructure around the country, so that we can continue to support the university and small business networks that create the opportunities for tomorrow.

UK Diagnostics Industry and Covid-19 Recovery

Debate between George Freeman and Rachael Maskell

Tuesday 10th May 2022 Commons Chamber

[George Freeman]

The hon. Gentleman makes an important point and invites me to signal again my support for what is going on in Northern Ireland. If we look at the cancer outcomes in Northern Ireland, the Queen’s University team that has been working on biomarkers and earlier detection has ended up driving not just investment, but much quicker and better outcomes for the people of Northern Ireland. The real power of the sector is that it delivers better healthcare for everybody within the values of the NHS, but also attracts investment and drives industry. I would go so far as to say that in the new landscape, companies such as Randox will develop affordable consumer diagnostic kits that can help drive earlier detection, building on to a digital interface. We can then support patients to get into trials earlier and drive research medicine. Belfast is on the frontline of that.

[Rachael Maskell (York Central) (Lab/Co-op)]

This evening’s debate has been excellent. In York, we had a company that was developing aptamers to be used in the diagnostic process. The Government did not have a grip on the governance or an understanding of what could be produced and the quality that that would bring. How is that mapping being done to ensure that every part of the manufacturing process is brought together?

[George Freeman]

The hon. Lady, not for the first time, makes an important point. As I am not a Minister in the Department of Health and Social Care, I had better defer to them on where they are on that specific mapping point. In terms of my responsibility at the Department for Business, Energy and Industrial Strategy, we are looking to grow the innovation economy by mapping the clusters of expertise around the country, including BioYorkshire, which I visited recently, and to ensure that we are aware of and supporting those clusters of research. Given that I have been invited to comment on other geographies, I will highlight how proud I am that the Norwich research park was the first place in the country to establish a local testing facility and local testing infrastructure to support it.

One thing the pandemic revealed was that, whether it is test and trace, data or epidemiological control, the best people to get on top of it are those on the ground locally. One of the lessons of the pandemic is that, yes, we need strong national leadership, but we also need to free up and trust the clinical and professional judgment on the ground.

For the record, it is important to speak about the scale of the diagnostics challenge in the pandemic. At peak, more than 700,000 PCR tests and 74,000 genomic sequences were done daily. It has been the most extraordinary turbocharging of our diagnostics infrastructure. I think everyone is aware of what we owe the diagnostics industry—that needs to be put on the record—but also that the infrastructure must be maintained for future events.

Genomic sequencing technology has been fundamental. The groundbreaking analyses of the combined SARS-CoV-2 genomic sequences and epidemiological data have supported the uploading of 2.7 million of 10.7 million genomes in GISAID—the global initiative on sharing avian influenza data. We are leaders in the global networks for genomic sequencing because of that genomics investment. More than 2 billion lateral flow tests have been provided across the UK.

I am conscious of the time. With permission, I will deal with the detailed questions that the hon. Member for Kirkcaldy and Cowdenbeath has raised in writing. I hope that I have reassured colleagues that we have absolutely learned the lesson that the diagnostics industry will never again be the poor relation. Emergencies require us to learn the lessons—we will not have got everything right, and the official inquiry is important. I would like to take the politics out of it and ensure that the clinical lessons are learned. I assure the hon. Gentleman that we are determined to ensure that the industry is put at the heart of our life sciences vision.

Question put and agreed to.

Oral Answers to Questions

Debate between George Freeman and Rachael Maskell

Tuesday 11th January 2022 Commons Chamber

[George Freeman]

I am grateful to the hon. Gentleman for raising that issue. With Queen’s University Belfast and the Randox cluster, Northern Ireland is a powerhouse in life sciences and both the Secretary of State and I have been to visit. I am delighted that the hon. Gentleman has made that point and will make sure that the Northern Ireland cluster is powerfully at the heart of our innovation strategy.

[Rachael Maskell (York Central) (Lab/Co-op)]

In York, we want to maintain momentum around the BioYorkshire project—York’s green new deal—so will the Minister set out when the project can apply for funding under the Biotechnology and Biological Sciences Research Council funding regime?

Oral Answers to Questions

Debate between George Freeman and Rachael Maskell

Tuesday 21st September 2021 Commons Chamber

[George Freeman]

I should be delighted to meet my hon. Friend soon to discuss that. Labcorp is a major global corporation whose investment in the new clinical pharmacology site is vital. It is in such companies that we need to be investing to drive private investment in research and development.

[Rachael Maskell (York Central) (Lab/Co-op)]

Time and again I have raised with the Government the opportunity to invest in BioYorkshire, which will create 4,000 jobs for my constituents, upskill 25,000 people, and deliver £5 billion in gross value added to the Government. Will the Minister meet me to discuss it? COP26 is just six weeks away, and not pursuing projects like this is holding back the improvements that we can make to our environment.

[George Freeman]

As I have said, I am wholly committed to ensuring that science innovation drives levelling up and regeneration, and I should be delighted to meet the hon. Lady. I shall be on my way to County Durham on Thursday, so perhaps I can meet her next week or the week after.

Oral Answers to Questions

Debate between George Freeman and Rachael Maskell

Thursday 24th October 2019 Commons Chamber

[George Freeman]

The Department shares the disappointment that the new rolling stock has been delayed. Pacer trains are not fit for purpose for the 21st century. Northern retired the first of its 102 Pacers in August, and it plans to remove two thirds by December 2019. Northern advises that, subject to receiving appropriate dispensation, up to 34 Pacers will remain in the fleet, but I assure the hon. Gentleman that we are determined to make sure the fleet is properly modernised.

[Rachael Maskell (York Central) (Lab/Co-op)]

Labour knows the true value of connecting towns and cities across the north. Our integrated transport plan will invest in public transport, in public ownership, to work for the passengers not the shareholders. We will start by investing £39 billion in the whole Crossrail for the north project. How much will the Minister commit to the project today—only £15 billion?

[George Freeman]

I think the nation will be interested to hear the Opposition Front Bench team announcing major plans for investment, given that their economic plans will see a massive loss of investment in this country and massive economic damage. We can fund good transport infrastructure and a good NHS only when we have economic growth. The truth is that this Government are proceeding with the biggest investment package in road, rail and infrastructure in this country since the Victorians—£72 billion—and we are spending more per head on passengers in the north than in the south. This Government have the interests of the north at their heart.

Cystic Fibrosis

Debate between George Freeman and Rachael Maskell

Tuesday 8th December 2015 Westminster Hall

[George Freeman]

My hon. Friend raises an important point. Over the past few decades, the NHS across the UK has played an inspiring role in leading a lot of the breakthroughs in new treatments, but we have become latterly a slower adopter of the very treatments we often helped to discover. That is partly because the pressure of an ageing society and the rising cost for the health system today of just treating existing conditions are extremely challenging. In some areas, that has made innovations appear a cost to the system, when in fact good innovations may come with a cost spike on day one but generally lead to downstream savings in years 2, 3 and 4.

My hon. Friend puts his finger on a profound challenge at the heart of this landscape: in order really to assess the impact of innovative treatments, we need a much better handle on the existing costs, many of which are hidden, that come with a diagnosis. For that reason, I am spearheading work in the Department of Health to drive through a system of per-patient costing, so that we can begin to get a much clearer handle on what a CF diagnosis means on day one for both the patient and the health economy. That will allow NICE and NHS England to develop much more intelligent systems for assessing whether an innovation really represents good value.

Genomics and informatics are changing the landscape; for that reason the Prime Minister has created my post and we have launched a series of initiatives. On genomics, we have launched a groundbreaking £300 million initiative to sequence the genomes from 100,000 NHS patients of cancer and rare diseases. We have also launched 11 genomic medicine centres across the NHS, so that genomics is fundamentally embedded in our health system. On informatics, we have released huge amounts of cohort data to drive research, and we just announced in the comprehensive spending review a major £3.5 billion programme to invest in NHS digital infrastructure to support that.

We have launched precision medicine and cell therapy catapult centres with the Medical Research Council and industry partners to lead in both understanding causal mechanisms of rare diseases and developing and accelerating new treatments. We continue to fund the excellent National Institute for Health Research, for which it is my privilege to be responsible, to the tune of £1 billion a year, and we committed this year in the CSR to fund it throughout this Parliament, at a cost of £5 billion. We have funded the £700 million Francis Crick Institute, and roughly £2 billion of the drugs budget is allocated to new medicines and new treatments in this Parliament.

There is a major commitment, in terms of science and funding, to trying to tackle this issue, but crucially we need policy reforms to ensure that breakthroughs in science can be harnessed for much quicker benefits for patients. That is what the accelerated access review and a number of other initiatives, such as the test bed programme and the vanguards I am running with NHS England, are about—trying to ensure we can change the pathways for getting innovation into our health system for much quicker patient benefit.

I want to say something about the accelerated access review and the specialist commissioning reforms that NHS England is putting in place. I know all Members here take an interest in this subject, so I hope they will be aware that I have launched the independent AAR to ask and answer one big question: what can we better do to harness the extraordinary infrastructure here in the UK in terms of our deep science research base, our NHS-NIHR research base and our NHS daily treatment platform?

The NHS is the fifth biggest organisation in the world, making millions of diagnoses and carrying out millions of treatments every day. Its original founding mission was to be a research organisation, but unless we better capture the data on those interventions, we are still practising, in many cases, blind medicine; we are not harnessing that intelligence enough to inform treatment.

I have asked that the AAR tackles three big questions. First, what can we do to allow the innovators—the developers of new drugs and innovations—quicker access to patients, to reach the all-important moment of proving an innovation works in patients? Secondly, what can we do to harness our leadership in genomics and informatics in order to create a more intelligent system for NICE and NHS England, with more flexibilities, so that they can assess, adopt, approve and reimburse innovations using real-time data about real patients? That will allow us to develop a more flexible set of pathways and adaptive tools with which to embrace this revolution.

When a drug comes to us with a genomic biomarker and we know that it will work for a certain sub-cohort of patients, that profoundly changes the risk dynamic of a traditional pharmaceutical clinical trials programme and should allow us to accelerate adoption for particular patient groups.

[Rachael Maskell]

Within those considerations, will the Minister also look at international evidence, so that we are looking at not only our own clinical trials but those on a global scale? Clearly, developments are global rather than just national.

[George Freeman]

The hon. Lady makes an important point. I have been to Washington three times and to Berlin, Paris and Brussels to highlight that while the UK is leading in this field, we need a transatlantic—European and American—agreement on how we move things forward. That is why I am convening and chairing a summit this afternoon with the Washington-based FasterCures campaign, which is a cross-party group on the Hill pushing for innovations in this space. I have been talking to the Commission about the European framework. I want the UK to be the best entry point into the European market, but I also want the European regulatory framework to be consistent and coherent; that is an important point.

The second question I have asked the AAR to look at is: what freedoms, flexibilities and new pathways can we envisage giving NICE and NHS England, particularly in the field of specialist commissioning? For CF, the decision to purchase ivacaftor is a national one, made by an NHS England specialist commissioning unit. I would like that unit to work much more closely with the Department of Health pricing team, so that where we can offer a company faster access to a key patient cohort, data and genomic information, we are able to do a much better deal with the company.

At the moment, we are operating the Translarna and Vimizim programme in the existing landscape. I share colleagues’ frustration, but it is important we go through due process. I do not think anyone wants a world in which Ministers decide what drugs come through on the basis of political pressure, tempting though it may be. I have done everything I can this year to expedite the existing process.

Following the positive news on Vimizim, I am hopeful about Translarna—a similar drug. NICE has been consulting on the process, and I believe the company has been engaging with NICE on pricing. I am hopeful that there will be a decision in the next few months to parallel the one on Vimizim, but that decision is not in my gift: it is up to NICE, which is rightly working on the basis of the very best clinical evidence.